The second type of medication that aims to improve memory and brain function in Alzheimer’s patients is Memantine (Nameda).
Past News ReleasesRSS
Toronto, ON (PRWEB) April 12, 2013
Bel Marra Health, who offers high-quality, specially formulated vitamins and nutritional supplements, is reporting on a new research that shows how patients on cholinesterase inhibitors are hospitalized for fainting 200% more than those not on these drugs.
As Bel Marra Health reports in its article (http://www.belmarrahealth.com/brain-function/are-prescription-memory-drugs-even-safe/), prescription memory drugs are often given to Alzheimer’s patients, and they are also prescribed ‘off-label’ to people with memory problems and disturbed brain function. Like all prescription medications, drugs that target the memory can cause a plethora of side-effects and health risks.
There are two main classes of medications that aim to enhance brain function and improve memory problems in Alzheimer’s patients. The first are classified as ‘cholinesterase inhibitors,’ (Donepezil, Rivastigmine or Galantamine) and they are approved for the treatment of early to moderate Alzheimer’s symptoms.
As the Bel Marra Health article reads, according to a study conducted at McGill University, people on cholinesterase inhibitors were hospitalized for fainting 200% more than those not on the drugs. The increased risk for fainting also means an increased risk for debilitating bone fractures and permanent disability. Patients on these drugs also have twice the likelihood for requiring a pacemaker implant.
The second type of medication that aims to improve memory and brain function in Alzheimer’s patients is Memantine (Nameda). Although the use of Memantine in non-Alzheimer’s patients is not approved by the FDA, physicians sometimes prescribe it to patients looking to improve memory and increase brain function.
According to an analysis of multiple studies on Memantine that was published in the Archives of Neurology, Memantine works no better than a placebo when it comes to treating patients who do not have severe Alzheimer’s disease. What’s more, current studies suggest that even those with mild to moderate Alzheimer’s disease experience little benefit from this drug.
Although Memantine appears to work no better than a placebo when it comes to enhancing the memory of non-Alzheimer’s patients, it sure does provide the user with some very real side-effects. Extreme tiredness, dizziness, confusion, sleepiness, constipation, coughing, pain throughout the body, and vomiting can all be caused by Memantine. In rare cases, this drug can also cause difficulty breathing, hallucinations, vertigo, a loss of consciousness and even comas.
According to Dr. Gill, Ontario Ministry of Health and Long-term Care Career Scientist “…the drugs are marketed as helping to preserve memory and improve function…but for a subset of people, the effect appears to be the exact opposite.” Furthermore, the risks associated with cholinesterase inhibitors and Memantine are too high to justify the use of these drugs by healthy individuals who simply desire better memory capabilities.
(SOURCE: “J Med Case Rep.” Memantine treatment for neuropsychiatric symptoms in a patient with probable idiopathic normal pressure hydrocephalus: a case report. April 5, 2013)
Bel Marra Health is the maker of “The Smart Pill” a high-quality nutritional supplement designed for brain health in formulations designed to address this specific health concern. All ingredients are backed with scientific evidence. Every product is tested for safety, quality, and purity at every stage of the manufacturing process. Furthermore, Bel Marra Health products are produced only in Health Canada approved facilities, going that extra mile to ensure our health conscious customers are getting top quality products. For more information on Bel Marra Health visit http://www.belmarrahealth.com or call 1-866-531-0466.